These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25828170)

  • 1. Imaging in prostate cancer with multiparametric magnetic resonance imaging and gallium positron emission tomography-computed tomography: 'the real deal'?
    Lawrentschuk N
    BJU Int; 2015 Apr; 115 Suppl 5():1-2. PubMed ID: 25828170
    [No Abstract]   [Full Text] [Related]  

  • 2. PET/CT in prostate cancer: an unmet clinical need.
    Mintz A
    Oncology (Williston Park); 2014 Dec; 28(12):1065-6. PubMed ID: 25738198
    [No Abstract]   [Full Text] [Related]  

  • 3. FDG PET/CT: normal variations and benign findings--translation to PET/MRI.
    Beheshti M; Kim CK
    PET Clin; 2014 Apr; 9(2):xiii-xiv. PubMed ID: 25030290
    [No Abstract]   [Full Text] [Related]  

  • 4. Massive pulmonary carcinoid tumor deemed inoperable until (68)Ga DOTATATE positron emission tomography/magnetic resonance imaging.
    Ordidge KL; Brown JM; Succony L; Navani N; Hardavella G; Lawrence DR; Fraioli F; Groves A; Janes SM
    Am J Respir Crit Care Med; 2014 Sep; 190(5):e16-7. PubMed ID: 25171317
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular imaging of advanced prostate cancer.
    Rossi PJ; Schuster DM
    Curr Probl Cancer; 2015; 39(1):29-32. PubMed ID: 25637931
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of small cell carcinoma of the prostate.
    Sahiner I; Akkas BE; Ucmak Vural G
    Rev Esp Med Nucl Imagen Mol; 2013; 32(3):193-5. PubMed ID: 23218515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging in Prostate Cancer: Magnetic Resonance Imaging and Beyond.
    Ludwig DR; Fraum TJ; Fowler KJ; Ippolito JE
    Mo Med; 2018; 115(2):135-141. PubMed ID: 30228705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer: combined FEC-PET/MRI improves diagnostic accuracy.
    Clyne M
    Nat Rev Urol; 2014 Jun; 11(6):306. PubMed ID: 24818855
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.
    Koo PJ; Kwak JJ; Pokharel S; Choyke PL
    Curr Oncol Rep; 2015 Dec; 17(12):56. PubMed ID: 26462919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography/CT versus MRI in liver metastasis: is there a winner?
    Grassetto G; Maffione AM; Rubello D
    J Med Imaging Radiat Oncol; 2014 Oct; 58(5):529-31. PubMed ID: 25287485
    [No Abstract]   [Full Text] [Related]  

  • 13. Positron emission tomography-magnetic resonance imaging in the evaluation of brain tumors: current status and future prospects.
    Nguyen N; Montagnese J; Rogers LR; Sher A; Wolansky L
    Semin Roentgenol; 2014 Jul; 49(3):275-89. PubMed ID: 25497912
    [No Abstract]   [Full Text] [Related]  

  • 14. Bone mass of the calvarium.
    Simoni P; Stulko J; Ben Mustapha S; Schoysman L; Bianchi E; Withofs N; Racaru T; Caers J; Alvarez-Miezentseva V
    Skeletal Radiol; 2013 Aug; 42(8):1157-9, 1185-7. PubMed ID: 23197077
    [No Abstract]   [Full Text] [Related]  

  • 15. PET tracers beyond FDG: normal variations and benign findings.
    Kim CK; Beheshti M
    PET Clin; 2014 Jul; 9(3):xi-xii. PubMed ID: 25030403
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluorodeoxyglucose positron emission tomography/magnetic resonance imaging: current status, future aspects.
    Rakheja R; Chandarana H; Ponzo F; Seltzer AL; Beltran LS; Geppert C; Friedman KP
    PET Clin; 2014 Apr; 9(2):237-52. PubMed ID: 25030285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study.
    Hitier-Berthault M; Ansquer C; Branchereau J; Renaudin K; Bodere F; Bouchot O; Rigaud J
    Int J Urol; 2013 Aug; 20(8):788-96. PubMed ID: 23279605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases.
    John SS; Zietman AL; Shipley WU; Harisinghani MG
    Int J Radiat Oncol Biol Phys; 2008; 71(1 Suppl):S43-7. PubMed ID: 18406936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body MR or PET-CT?
    Schmidt GP
    Eur J Radiol; 2012 Sep; 81 Suppl 1():S142-3. PubMed ID: 23083566
    [No Abstract]   [Full Text] [Related]  

  • 20. Current status and future needs for standards of radionuclides used in positron emission tomography.
    Zimmerman BE
    Appl Radiat Isot; 2013 Jun; 76():31-7. PubMed ID: 23078834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.